Journal article

Efficacy of erlotinib in patients with advanced Non-small-cell Lung Cancer (NSCLC): Analysis of the Australian subpopulation of the TRUST study

Michael Boyer, Keith Horwood, Nick Pavlakis, Paul De Souza, Michael Millward, Brian Stein, Michael Johnston, Fiona Abell, Danny Rischin

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | WILEY-BLACKWELL | Published : 2012

Abstract

AIMS: The efficacy of erlotinib (Tarceva, Roche Products, Dee Why, Australia) has been demonstrated in patients with advanced non-small-cell lung cancer (NSCLC). Tarceva lung cancer survival treatment (TRUST) is an open-label, single-arm, phase IV global trial which investigated erlotinib in advanced NSCLC patients who had failed prior therapy or were unsuitable for chemo/radiotherapy. The aim of this analysis was to report the safety and efficacy of erlotinib in the Australian patient subpopulation. METHODS: Patients with stage IIIB/IV NSCLC progressing after standard systemic chemotherapy or unsuitable to receive chemo/radiotherapy were eligible for the study. The patients were treated wit..

View full abstract